Login

Keenova Therapeutics plc SEC Filings

Filed On Filing
12 Nov 2026 Form 4
10 Nov 2026 10-Q
10 Nov 2026 SCHEDULE 13D/A
10 Nov 2026 8-K: Results of Operations and Financial Condition

Continued Strong Performance Driven by Growth in Acthar® Gel1 and XIAFLEX®2

09 Nov 2026 Form 4: Goldentree Asset Management Lp, 10% owner and 2 others

Bought 145,716 shares ($13M) · Bought 150,000 shares ($13.4M)

16 Oct 2026 Form 4: Goldentree Asset Management Lp, 10% owner and 2 others

Bought 137,000 shares ($12.3M)

06 Oct 2026 Form 4: Goldentree Asset Management Lp, 10% owner and 2 others

Bought 463,000 shares ($42.1M)

06 Oct 2026 SCHEDULE 13D/A
11 Aug 2026 10-Q
11 Aug 2026 8-K: Results of Operations and Financial Condition

Strong Performance Driven by Growth in Acthar® Gel1 and XIAFLEX®2

03 Aug 2026 8-K: Other Events

On July 31, 2026, Keenova Therapeutics plc (the “Company”) closed the previously disclosed sale of its Percocet and Endocet businesses (the “Business”) to Par Health, Inc (“Par Health”). Consideration for the transaction is expected to t...

23 Jul 2026 Form 4: Williamson Susan Ann, EVP & Chief Compliance Officer

Gave up 571 shares to cover exercise price or tax

23 Jul 2026 Form 4: Basso Tracy, EVP & CHRO

Gave up 763 shares to cover exercise price or tax

23 Jul 2026 Form 4: Stouch Cheryl Ann, EVP & Chief Info Officer

Gave up 328 shares to cover exercise price or tax

17 Jul 2026 Form 4: Langlois Sophia J., Director

Granted 4,406 Restricted Stock Units

17 Jul 2026 Form 4: Yoskowitz Marc J, Director

Granted 4,406 Restricted Stock Units

17 Jul 2026 Form 4: Hirsch Scott, Director

Granted 4,406 Restricted Stock Units

17 Jul 2026 Form 4: Zinman Jon, Director

Granted 4,406 Restricted Stock Units

17 Jul 2026 Form 4: Efron Paul, Director

Granted 4,406 Restricted Stock Units

17 Jul 2026 Form 4: Donato Leslie E, Director

Granted 4,406 Restricted Stock Units

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support